US › Healthcare

Nuvation Bio Inc (NUVB)

US · Healthcare · Biotechnology

$6.44+4.55%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$83.2M
Revenue YoY
+2598.7%
Net profit
$5.4M
Profit YoY
+110.1%
EPS
$0.01
EPS estimate
$-0.04
Net margin
6.5%

EPS came in at 0.01 against a street estimate of -0.04 — a beat of 123.1%.

Key statistics

Market cap
$2.20B
Forward P/E
0.0
P/B
6.90
Book value
$0.92
EPS (TTM)
$-0.43
52-week high
$9.75
52-week low
$2.18
50-day MA
$5.56
200-day MA
$5.70
Beta
1.53

Analyst view

Analysts rate Nuvation Bio Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $12.78.

Shareholding

Insiders
18.60%
Institutions
64.98%

Recent filings & reports

DocumentDate
Company announcement · Q2 20262026-07-06
Material agreement · Q2 20262026-06-30
Shareholder vote results · Q2 20262026-05-27
Results announced · Q2 20262026-05-04
Quarterly report · Q1 20262026-05-04
Proxy statement · Q2 20262026-04-10
Annual report FY20252026-03-02
Quarterly report · Q3 20252025-11-03

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nuvation Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.